Immunogenicity of Hepatitis B Virus Vaccine (Heptavax-B)—Response of Healthy Adults
AUTOR(ES)
Beasley, R. Palmer
RESUMO
We vaccinated 30 healthy adults who were susceptible to hepatitis B virus with 20 μg of Merck Sharp & Dohme vaccine at zero, one and six months and measured their antibody (anti-HBs) response weekly for four weeks and monthly for at least seven months. A month following the first dose 40% had antibodies and 90% were positive for anti-HBs a month following the second dose. The third dose raised the response rate to 93.3% but its major effect was to substantially raise the titer of virtually all of the vaccinees. Two persons had no antibody response to vaccination and four others were hyporesponders. No complications or significant side effects were observed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1011077Documentos Relacionados
- Immunogenicity in humans of an edible vaccine for hepatitis B
- Response to diphtheria booster vaccination in healthy adults: vaccine trial
- Safety and Immunogenicity of Increasing Doses of a Clostridium difficile Toxoid Vaccine Administered to Healthy Adults
- Safety and Immunogenicity of a Proteosome-Shigella flexneri 2a Lipopolysaccharide Vaccine Administered Intranasally to Healthy Adults
- Immunogenicity of peptide fusions to hepatitis B virus core antigen.
